Dermatology Online Journal · 2009 · 26 citations · 0 references
MedicinePharmacologyPharmacotherapyClinical ImmunologyImmunopharmacologyImmunoregulationAutoimmune Skin DiseasesImmunomodulatory Drug TherapyImmunomodulatory DrugsImmunopathology Of SkinImmunostimulatory TherapyInflammatory Skin DiseasesCutaneous ImmunologyDermatologic Adverse EventsImmune System ModulationOff-label Drug Use RegulationSystemic ImmunomodulatorsTopical Antiallergic TherapyTopical ImiquimodTopical Immunomodulators
Due to the ability of imiquimod (Aldara, 3M Pharmaceuticals) to rapidly and potently stimulate both innate and adaptive arms of the immune system, imiquimod has rapidly been recognized as a potential candidate for off-label use in over 60 conditions as presented in numerous case reports, letters, and small trials. It is our goal to examine and consolidate this impressive body of literature in order to provide the practicing dermatologist with a quick reference of the conditions that have been successfully treated with imiquimod, the dosages used, and the success rates of treatments.